Cargando…
3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma
SIMPLE SUMMARY: Follicular lymphoma is an indolent B cell lymphoproliferative disorder of transformed follicular center B cells, which accounts for 20–30 percent of all non-Hodgkin lymphoma (NHL) cases. Although huge efforts have been made in the last 10 years, this pathology is still considered as...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036410/ https://www.ncbi.nlm.nih.gov/pubmed/33804934 http://dx.doi.org/10.3390/cancers13071490 |
_version_ | 1783676903594393600 |
---|---|
author | Gava, Fabien Faria, Carla Gravelle, Pauline Valero, Juan G. Dobaño-López, Cèlia Morin, Renaud Norlund, Marine Gomes, Aurélie Lagarde, Jean-Michel Rossi, Cédric Bordenave, Julie Pieruccioni, Laetitia Rouquette, Jacques Matas-Céspedes, Alba Fournié, Jean-Jacques Ysebaert, Loïc Laurent, Camille Pérez-Galán, Patricia Bezombes, Christine |
author_facet | Gava, Fabien Faria, Carla Gravelle, Pauline Valero, Juan G. Dobaño-López, Cèlia Morin, Renaud Norlund, Marine Gomes, Aurélie Lagarde, Jean-Michel Rossi, Cédric Bordenave, Julie Pieruccioni, Laetitia Rouquette, Jacques Matas-Céspedes, Alba Fournié, Jean-Jacques Ysebaert, Loïc Laurent, Camille Pérez-Galán, Patricia Bezombes, Christine |
author_sort | Gava, Fabien |
collection | PubMed |
description | SIMPLE SUMMARY: Follicular lymphoma is an indolent B cell lymphoproliferative disorder of transformed follicular center B cells, which accounts for 20–30 percent of all non-Hodgkin lymphoma (NHL) cases. Although huge efforts have been made in the last 10 years, this pathology is still considered as incurable, leaving open the discovery and testing of new therapeutic targets requiring relevant preclinical models. Here, we report a realistic 3D model of t (14;18)-positive B-NHL cell culture (ultra-low attachment (ULA)-multicellular aggregates of lymphoma cells (MALC)), which monitored by state-of-the-art 2D and 3D imaging, allows more robust drug testing. ABSTRACT: Follicular lymphoma (FL) is an indolent B cell lymphoproliferative disorder of transformed follicular center B cells, which accounts for 20–30 percent of all non-Hodgkin lymphoma (NHL) cases. Great advances have been made to identify the most relevant targets for precision therapy. However, no relevant models for in vitro studies have been developed or characterized in depth. To this purpose, we generated a 3D cell model from t(14;18)-positive B-NHL cell lines cultured in ultra-low attachment 96-well plates. Morphological features and cell growth behavior were evaluated by classical microscopy (2D imaging) and response to treatment with different drugs was evaluated by a high-content analysis system to determine the robustness of the model. We show that the ultra-low attachment (ULA) method allows the development of regular, spherical and viable ULA-multicellular aggregates of lymphoma cells (MALC). However, discrepancies in the results obtained after 2D imaging analyses on drug-treated ULA-MALC prompted us to develop 3D imaging and specific analyses. We show by using light sheet microscopy and specifically developed 3D imaging algorithms that 3D imaging and dedicated analyses are necessary to characterize morphological properties of 3D models and drug effects. This study proposes a new method, but also imaging tools and informatic solutions, developed for FL necessary for future preclinical studies. |
format | Online Article Text |
id | pubmed-8036410 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80364102021-04-12 3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma Gava, Fabien Faria, Carla Gravelle, Pauline Valero, Juan G. Dobaño-López, Cèlia Morin, Renaud Norlund, Marine Gomes, Aurélie Lagarde, Jean-Michel Rossi, Cédric Bordenave, Julie Pieruccioni, Laetitia Rouquette, Jacques Matas-Céspedes, Alba Fournié, Jean-Jacques Ysebaert, Loïc Laurent, Camille Pérez-Galán, Patricia Bezombes, Christine Cancers (Basel) Article SIMPLE SUMMARY: Follicular lymphoma is an indolent B cell lymphoproliferative disorder of transformed follicular center B cells, which accounts for 20–30 percent of all non-Hodgkin lymphoma (NHL) cases. Although huge efforts have been made in the last 10 years, this pathology is still considered as incurable, leaving open the discovery and testing of new therapeutic targets requiring relevant preclinical models. Here, we report a realistic 3D model of t (14;18)-positive B-NHL cell culture (ultra-low attachment (ULA)-multicellular aggregates of lymphoma cells (MALC)), which monitored by state-of-the-art 2D and 3D imaging, allows more robust drug testing. ABSTRACT: Follicular lymphoma (FL) is an indolent B cell lymphoproliferative disorder of transformed follicular center B cells, which accounts for 20–30 percent of all non-Hodgkin lymphoma (NHL) cases. Great advances have been made to identify the most relevant targets for precision therapy. However, no relevant models for in vitro studies have been developed or characterized in depth. To this purpose, we generated a 3D cell model from t(14;18)-positive B-NHL cell lines cultured in ultra-low attachment 96-well plates. Morphological features and cell growth behavior were evaluated by classical microscopy (2D imaging) and response to treatment with different drugs was evaluated by a high-content analysis system to determine the robustness of the model. We show that the ultra-low attachment (ULA) method allows the development of regular, spherical and viable ULA-multicellular aggregates of lymphoma cells (MALC). However, discrepancies in the results obtained after 2D imaging analyses on drug-treated ULA-MALC prompted us to develop 3D imaging and specific analyses. We show by using light sheet microscopy and specifically developed 3D imaging algorithms that 3D imaging and dedicated analyses are necessary to characterize morphological properties of 3D models and drug effects. This study proposes a new method, but also imaging tools and informatic solutions, developed for FL necessary for future preclinical studies. MDPI 2021-03-24 /pmc/articles/PMC8036410/ /pubmed/33804934 http://dx.doi.org/10.3390/cancers13071490 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Article Gava, Fabien Faria, Carla Gravelle, Pauline Valero, Juan G. Dobaño-López, Cèlia Morin, Renaud Norlund, Marine Gomes, Aurélie Lagarde, Jean-Michel Rossi, Cédric Bordenave, Julie Pieruccioni, Laetitia Rouquette, Jacques Matas-Céspedes, Alba Fournié, Jean-Jacques Ysebaert, Loïc Laurent, Camille Pérez-Galán, Patricia Bezombes, Christine 3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma |
title | 3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma |
title_full | 3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma |
title_fullStr | 3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma |
title_full_unstemmed | 3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma |
title_short | 3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma |
title_sort | 3d model characterization by 2d and 3d imaging in t(14;18)-positive b-nhl: perspectives for in vitro drug screens in follicular lymphoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036410/ https://www.ncbi.nlm.nih.gov/pubmed/33804934 http://dx.doi.org/10.3390/cancers13071490 |
work_keys_str_mv | AT gavafabien 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma AT fariacarla 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma AT gravellepauline 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma AT valerojuang 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma AT dobanolopezcelia 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma AT morinrenaud 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma AT norlundmarine 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma AT gomesaurelie 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma AT lagardejeanmichel 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma AT rossicedric 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma AT bordenavejulie 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma AT pieruccionilaetitia 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma AT rouquettejacques 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma AT matascespedesalba 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma AT fourniejeanjacques 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma AT ysebaertloic 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma AT laurentcamille 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma AT perezgalanpatricia 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma AT bezombeschristine 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma |